Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Biliary Tract Neoplasms × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 344 Brain Neoplasms 133 Glioma 131 Gliosarcoma 118 Astrocytoma 97 Central Nervous System Neoplasms 93 Oligodendroglioma 64 Melanoma 59 Neuroblastoma 37 Medulloblastoma 28 Neoplasms 25 Recurrence 24 Neoplasm Metastasis 23 Ependymoma 23 Sarcoma, Ewing 19 Sarcoma 17 Rhabdomyosarcoma 15 Diffuse Intrinsic Pontine Glioma 15 Ovarian Neoplasms 13 Breast Neoplasms 13 Lymphoma 12 Neuroendocrine Tumors 11 Lung Neoplasms 10 Choroid Plexus Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Small Cell Lung Carcinoma 9 Osteosarcoma 9 Neuroectodermal Tumors, Primitive 9 Optic Nerve Glioma 8 Neuroectodermal Tumors, Primitive, Peripheral 8

Interventions

Gemcitabine 75 Cisplatin 60 Capecitabine 31 Oxaliplatin 29 durvalumab 24 Fluorouracil 21 pembrolizumab 19 Leucovorin 19 S 1 (combination) 13 Irinotecan 11 lenvatinib 9 Nivolumab 9 Bevacizumab 8 tremelimumab 7 Injections 7 130-nm albumin-bound paclitaxel 7 apatinib 6 Trastuzumab 6 Docetaxel 6 surufatinib 5 camrelizumab 5 Immune Checkpoint Inhibitors 5 Carboplatin 5 Albumin-Bound Paclitaxel 5 titanium silicide 4 irinotecan sucrosofate 4 gemcitabine-oxaliplatin regimen 4 envafolimab 4 Folfox protocol 4 Drug Therapy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡